$RLFTF DD (opinion) Post by DanG on Yh-0 Hi fel
Post# of 653
(Total Views: 320)
Posted On: 04/29/2021 3:52:56 PM
$RLFTF DD (opinion) Post by DanG on Yh-0
Hi fellow longs:
Time for one of my rare posts. I hope it helps.
1. There is no reason to worry based on the stock price. Volume is generally low and the ups and downs we are seeing are not atypical for a bio stock in the absense of concrete news.
2. All of the information we have about the trial results is positive. FDA approval generally takes months for an EUA and the company needs to have all its ducks in a row. DR. J is one of the most experienced people in the world at this and if that does not bring you confidence you really should sell.
3. The trial with Remdesivir is a huge deal for this stock as all past results suggest the results will favor Aviptadil.
4. We don't yet know if the inhaled version of Aviptadil will be effective. That is really the biggest unknown impacting the potential value of the company.
5. My guess is the conflict between Relief and NeiroRx is being driven behind the scenes by BRPA. I am not terribly worried about itbut share the perspective that it is not helping the current share price.
6. I have 600,000 shares and have no intention of selling
In fact I have steadily added shares since I first bought in August of 2020. Would buy more now if I could, although I don't suggest others do so. This is a high risk investment, as are most bio stocks.
Hi fellow longs:
Time for one of my rare posts. I hope it helps.
1. There is no reason to worry based on the stock price. Volume is generally low and the ups and downs we are seeing are not atypical for a bio stock in the absense of concrete news.
2. All of the information we have about the trial results is positive. FDA approval generally takes months for an EUA and the company needs to have all its ducks in a row. DR. J is one of the most experienced people in the world at this and if that does not bring you confidence you really should sell.
3. The trial with Remdesivir is a huge deal for this stock as all past results suggest the results will favor Aviptadil.
4. We don't yet know if the inhaled version of Aviptadil will be effective. That is really the biggest unknown impacting the potential value of the company.
5. My guess is the conflict between Relief and NeiroRx is being driven behind the scenes by BRPA. I am not terribly worried about itbut share the perspective that it is not helping the current share price.
6. I have 600,000 shares and have no intention of selling
In fact I have steadily added shares since I first bought in August of 2020. Would buy more now if I could, although I don't suggest others do so. This is a high risk investment, as are most bio stocks.
(0)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ